Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary

Background & Aims: Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint inhibitors are effective in treating many solid cancers, but immune checkpoint inhibitor monotherapy has no clear benefit in iC...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2021-01-01
Serier:	Cellular and Molecular Gastroenterology and Hepatology
Fag:	Intrahepatic Cholangiocarcinoma Anti–PD-1 Monoclonal Antibody Trametinib
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2352345X21001004
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!